30
Participants
Start Date
October 2, 2019
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2027
Nivolumab Injection
Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
Ipilimumab Injection
Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine, Baltimore
Johns Hopkins University, Baltimore
University of Texas M.D. Anderson Cancer Center, Houston
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER